vs
Amphastar Pharmaceuticals, Inc.（AMPH）与OneStream, Inc.（OS）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是OneStream, Inc.的1.1倍（$183.1M vs $163.7M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 0.6%，领先12.7%），OneStream, Inc.同比增速更快（23.6% vs -1.8%），OneStream, Inc.自由现金流更多（$25.6M vs $24.6M），过去两年OneStream, Inc.的营收复合增速更高（21.8% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Blue Stream面向美国佛罗里达州科勒尔斯普林斯、韦斯顿两地的居民及商业客户，提供有线电视、有线固话、数字录像服务，以及最高速率达1G的宽带互联网接入服务，深耕当地通信市场，为用户提供稳定可靠的多元通信解决方案。
AMPH vs OS — 直观对比
营收规模更大
AMPH
是对方的1.1倍
$163.7M
营收增速更快
OS
高出25.4%
-1.8%
净利率更高
AMPH
高出12.7%
0.6%
自由现金流更多
OS
多$1.1M
$24.6M
两年增速更快
OS
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $163.7M |
| 净利润 | $24.4M | $999.0K |
| 毛利率 | 46.8% | 69.8% |
| 营业利润率 | 19.4% | -3.2% |
| 净利率 | 13.3% | 0.6% |
| 营收同比 | -1.8% | 23.6% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHOS
| Q4 25 | $183.1M | $163.7M | ||
| Q3 25 | $191.8M | $154.3M | ||
| Q2 25 | $174.4M | $147.6M | ||
| Q1 25 | $170.5M | $136.3M | ||
| Q4 24 | $186.5M | $132.5M | ||
| Q3 24 | $191.2M | $129.1M | ||
| Q2 24 | $182.4M | $117.5M | ||
| Q1 24 | $171.8M | $110.3M |
净利润AMPHOS
| Q4 25 | $24.4M | $999.0K | ||
| Q3 25 | $17.4M | $-8.8M | ||
| Q2 25 | $31.0M | $-18.4M | ||
| Q1 25 | $25.3M | $-24.0M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-171.9M | ||
| Q2 24 | $37.9M | $-7.8M | ||
| Q1 24 | $43.2M | $-5.0M |
毛利率AMPHOS
| Q4 25 | 46.8% | 69.8% | ||
| Q3 25 | 51.4% | 68.1% | ||
| Q2 25 | 49.6% | 68.6% | ||
| Q1 25 | 50.0% | 68.0% | ||
| Q4 24 | 46.5% | 66.8% | ||
| Q3 24 | 53.3% | 50.1% | ||
| Q2 24 | 52.2% | 68.5% | ||
| Q1 24 | 52.4% | 69.1% |
营业利润率AMPHOS
| Q4 25 | 19.4% | -3.2% | ||
| Q3 25 | 13.2% | -11.3% | ||
| Q2 25 | 24.2% | -21.8% | ||
| Q1 25 | 21.9% | -29.3% | ||
| Q4 24 | 24.2% | -35.8% | ||
| Q3 24 | 29.8% | -197.6% | ||
| Q2 24 | 30.3% | -9.8% | ||
| Q1 24 | 27.9% | -4.9% |
净利率AMPHOS
| Q4 25 | 13.3% | 0.6% | ||
| Q3 25 | 9.0% | -5.7% | ||
| Q2 25 | 17.8% | -12.5% | ||
| Q1 25 | 14.8% | -17.6% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -133.1% | ||
| Q2 24 | 20.8% | -6.7% | ||
| Q1 24 | 25.1% | -4.5% |
每股收益（稀释后）AMPHOS
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | $-1.06 | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $693.6M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $504.7M |
| 总资产 | $1.6B | $1.0B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHOS
| Q4 25 | $282.8M | $693.6M | ||
| Q3 25 | $276.2M | $653.9M | ||
| Q2 25 | $231.8M | $652.1M | ||
| Q1 25 | $236.9M | $593.9M | ||
| Q4 24 | $221.6M | $544.2M | ||
| Q3 24 | $250.5M | $495.5M | ||
| Q2 24 | $217.8M | $140.5M | ||
| Q1 24 | $289.6M | — |
总债务AMPHOS
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHOS
| Q4 25 | $788.8M | $504.7M | ||
| Q3 25 | $776.7M | $472.1M | ||
| Q2 25 | $757.5M | $458.2M | ||
| Q1 25 | $751.3M | $412.9M | ||
| Q4 24 | $732.3M | $386.2M | ||
| Q3 24 | $727.7M | $458.2M | ||
| Q2 24 | $713.3M | $97.5M | ||
| Q1 24 | $672.4M | $102.5M |
总资产AMPHOS
| Q4 25 | $1.6B | $1.0B | ||
| Q3 25 | $1.7B | $949.4M | ||
| Q2 25 | $1.6B | $910.5M | ||
| Q1 25 | $1.6B | $867.3M | ||
| Q4 24 | $1.6B | $823.2M | ||
| Q3 24 | $1.5B | $750.1M | ||
| Q2 24 | $1.5B | $379.7M | ||
| Q1 24 | $1.6B | — |
负债/权益比AMPHOS
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $25.8M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $25.6M |
| 自由现金流率自由现金流/营收 | 13.4% | 15.7% |
| 资本支出强度资本支出/营收 | 4.5% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.35× | 25.79× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $95.6M |
8季度趋势，按日历期对齐
经营现金流AMPHOS
| Q4 25 | $32.9M | $25.8M | ||
| Q3 25 | $52.6M | $5.0M | ||
| Q2 25 | $35.6M | $29.7M | ||
| Q1 25 | $35.1M | $36.2M | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $60.0M | $2.4M | ||
| Q2 24 | $69.1M | $8.1M | ||
| Q1 24 | $55.3M | $25.5M |
自由现金流AMPHOS
| Q4 25 | $24.6M | $25.6M | ||
| Q3 25 | $47.2M | $4.8M | ||
| Q2 25 | $25.0M | $29.4M | ||
| Q1 25 | $24.4M | $35.8M | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | $1.3M | ||
| Q2 24 | $63.1M | $7.7M | ||
| Q1 24 | $46.5M | $24.9M |
自由现金流率AMPHOS
| Q4 25 | 13.4% | 15.7% | ||
| Q3 25 | 24.6% | 3.1% | ||
| Q2 25 | 14.3% | 19.9% | ||
| Q1 25 | 14.3% | 26.3% | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | 1.0% | ||
| Q2 24 | 34.6% | 6.6% | ||
| Q1 24 | 27.1% | 22.5% |
资本支出强度AMPHOS
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.3% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | 0.8% | ||
| Q2 24 | 3.3% | 0.3% | ||
| Q1 24 | 5.1% | 0.6% |
现金转化率AMPHOS
| Q4 25 | 1.35× | 25.79× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
